Malvern Biopharm Halts Hepatitis B Drug Study Enrollments

A biopharmacuetical firm based out of Malvern has been forced to halt enrollments into one of its drug trial programs, according to a release from the company.

TetraLogic Pharmaceuticals Corporation says it temporary halted the acceptance of new patients into the study of birinipant, a drug being developed for cancer treatment that may have uses to treat Hepatitis B. The Hepatitis B study is being conducted in Australia, where the first cohort of patients were observed developing cranial nerve palsies.

According to Philadelphia Business Journal, the announcement caused TetraLogic’s stock to plummet 47 percent, from $3.78 per share to $1.99.